ACE2 and non-small cell lung carcinoma: During ACE suppression (including ACE2 high status and ACEI-treated condition), NSCLC patients or animal model gained better outcomes, and in addition, this benefit might be achieved by means of both reduced MV and increased VM formation, which seems to contradict general knowledge.